Autologous bone marrow transplantation (BMT) and peripheral stem cell transplantation (PSCT) are being used increasingly to treat a variety of neoplasms, including both hematologic malignancies and solid tumors. There are few studies that specifically examine the incidence of infectious complications after these procedures [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Most of these studies combine data from patients who receive these therapies for the treatment of a variety of underlying malignancies.
Autologous bone marrow transplantation (BMT) and peripheral stem cell transplantation (PSCT) are being used increasingly to treat a variety of neoplasms, including both hematologic malignancies and solid tumors. There are few studies that specifically examine the incidence of infectious complications after these procedures [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Most of these studies combine data from patients who receive these therapies for the treatment of a variety of underlying malignancies.
Furthermore, studies that include heterogeneous pa-tients with hematologic malignancies, such as acute leukemia, and with solid tumors, such as breast cancer, may not accurately characterize the risk of infectious complications for patients with a particular underlying malignancy. Knowledge of the specific incidence and type of infections is important for planning appropriate strategies for the prevention and empiric treatment of infections. Additionally, most previous studies have concentrated on infections in the immediate posttransplantation period. An understanding of the incidence of infectious complications during the first year after autologous BMT or PSCT has important implications as well. In this study, we review the infectious complications of 127 consecutive patients who underwent highdose chemotherapy followed by either autologous BMT or PSCT for the treatment of breast cancer at the University of Pennsylvania Medical Center from 1991 to 1995. Infections in the immediate posttransplantation Table 1 . Antimicrobial prophylaxis and growth factor use in 127 consecutive patients who underwent autologous autologous bone marrow transplantation or peripheral stem cell transplantation for breast cancer. setting and infections during the 1 year of outpatient followup were recorded.
PATIENTS AND METHODS
All consecutive patients who received high-dose chemotherapy followed by autologous BMT or PSCT for the treatment of breast cancer during the study period (1 May 1991-31 March 1995) were identified through an oncology log. University of Pennsylvania Medical Center inpatient records from the time of transplantation through the following year were reviewed. Outpatient records at the Hospital of the University of Pennsylvania Cancer Center were reviewed for the year after discharge from the transplantation hospitalization. We collected information on the following: patient demographics, comorbid diseases, type and stage of breast cancer, the protocol used for transplantation, the results of pretransplantation viral serology studies, the use of prophylactic and empiric antimicrobial agents and colony-stimulating factors, duration of fever and neutropenia, all infectious complications, and mortality.
Definitions. Neutropenia was defined as an absolute neutrophil count of р500 cells/mm 3 . Duration of neutropenia was defined as the number of days on which the patient's absolute neutrophil count was р500 cells/mm 3 . Fever was defined as temperature of у38ЊC. All positive results of blood cultures were deemed significant unless it was documented in the medical record that a culture was thought to be contaminated, and no changes in treatment regimen were made. The diagnosis of pneumonia was made on the basis of fever with a radiographically compatible pulmonary infiltrate. Other infections were considered clinically documented in the absence of definitive culture results; relevant examples include sinusitis, cellulitis, and oral candidiasis.
Treatment protocols. There were 5 protocols used for the treatment of breast cancer during the study period: 2 used autologous BMT and 3 used PSCT. Patients fell into 3 clinical groups: high-risk breast cancer (stage II and IIa disease with positive test results from у4 lymph nodes), inoperable locally advanced or advanced inflammatory breast cancer, and metastatic breast cancer. Chemotherapy conditioning regimens differed by protocol. All patients received cyclophosphamide (6 g/m 2 ) and thiotepa (500 mg/m 2 ). Some patients also received carboplatin (800 mg/m 2 ) as per protocol. All patients had Hickman catheters (Bard Access Systems) placed before receiving chemotherapy.
Infection control and anti-infection prophylaxis. Patients were cared for in individual high-efficiency particulate airfiltered, positive-pressure rooms. When patients were neutropenic, they were maintained on bacteria-controlled diets, without fresh fruits or vegetables. Prophylactic gut decontamination was not used in any protocol. The use of antibacterial, antifungal, and antiviral prophylaxis is displayed in table 1. Routine screening for cytomegalovirus infection was not performed.
All patients except one received either granulocyte colonystimulating factor (5 mg/kg per day) or granulocyte-macrophage colony-stimulating factor (250 mg/m 2 per day) from the day of transplantation until they were no longer neutropenic for at least 3 days. For patients with febrile neutropenia, the initial evaluation consisted of physical examination and performance of a urine culture, a chest radiograph, and culture of 2 sets of blood samples (by use of the BACTEC system). For patients with persistent febrile neutropenia, samples of blood for culture were obtained at 24-h intervals; 1 set of samples was obtained through the central venous catheter and 1 set peripherally. Ceftazidime was used as standard empiric therapy for febrile neutropenia. Vancomycin was added if there was suspicion of a gram-positive infection, and amphotericin B (AmB) was added, at the discretion of the physician, for persistent fever.
When patients were discharged, they were maintained on fluconazole therapy until posttransplantation day 100 (as mandated by the oncologic study protocols), after which they received no more antimicrobial prophylaxis. Outpatient follow-up was performed weekly for the first month after transplantation, then monthly until day 100, and then every 2-3 months.
Statistical analysis. Epi Info software (Centers for Disease Control and Prevention) was used for all statistical analyses. Categorical variables were compared by use of x 2 tests, and continuous variables were analyzed by use of t tests. P ! .05 was considered statistically significant. All tests were 2-sided.
RESULTS
During the study period, 130 patients underwent high-dose chemotherapy followed by autologous BMT or PSCT. Inpatient records were available for 127 of these patients. Thirty-four (27%) of 127 patients underwent autologous BMT, and 93 The microbiologically documented infections that occurred during the hospitalization for transplantation are summarized in tables 3 and 4. Bacteremia was the most common infection, occurring in 17 patients (13%), followed by Clostridium difficile colitis, seen in 14 patients (11%). Only 1 invasive fungal infection was documented. The patient with the fungal infection developed transient candidemia due to Candida albicans and evidence of candida retinitis. She had previously received antifungal prophylaxis with fluconazole for 2 days only. She responded to a course of AmB followed by fluconazole. Ten patients had bacterial urinary tract infections.
Clinically documented infections during the hospitalization (table 3) included catheter-related infections (catheter-site cellulitis or tunnel infection;
), mucocutaneous candidiasis n p 20 ( ), pneumonia ( ), sinusitis ( ), cellulitis not n p 14 n p 5 n p 4 associated with a catheter site ( ), and perirectal abscess, n p 5 typhlitis, and pharyngitis ( each). There were no perin p 1 transplantation cytomegalovirus infections documented.
The mean duration (‫ע‬SD) of neutropenia was days. 10 ‫ע‬ 4 Patients with neutropenia for 110 days did not have a significantly increased risk of infection or death. All patients except 1 received colony-stimulating factors. Of patients who received growth factor support, those who received granulocyte colonystimulating factor had a significantly shorter mean duration of neutropenia than those who received granulocyte-macrophage colony-stimulating factor (9 vs. 12 days;
). All but 3 P ! .001 patients (98%) experienced fever, and all but 1 patient received empiric broad-spectrum antibiotics.
Forty patients (31%) received AmB at some point during their hospitalization. Use of AmB was more common in patients with neutropenia for у10 days (55% vs. 14%; OR, 7.44; ) and P ! .001 in patients undergoing autologous BMT (59% vs. 22%; OR, 5.21; ) or receiving granulocyte-macrophage colony-stimulat-P ! .001 ing factor (45% vs. 25%; OR, 2.44;
). Patients who took P p .047 fluconazole prophylaxis were less likely to receive AmB (24% vs. 50%; OR, 0.32; ) than those who did not receive it. P p .009 Thirteen patients (10%) developed C. difficile colitis. The patients who developed C. difficile colitis did not differ significantly from the overall study group in age, duration of neutropenia, duration of hospitalization, or duration of antibiotic therapy. Notably, however, 7 of these 13 patients' hospital stays overlapped the hospital stay of at least 1 other patient with C. difficile colitis, which suggests possible nosocomial spread of the infection.
Four patients (3%) died during transplantation: 1 of polymicrobial sepsis, 2 with possible sepsis (hypotension, fever, and negative cultures), and another of suspected hepatic veno-occlusive disease. The mean duration of neutropenia was 15 days, which was significantly longer than the mean duration of neutropenia of the survivors (10 days;
). P p .011 Outpatient infections in the year after transplantation are outlined in table 5. Of the 111 patients who had available outpatient charts, 12 (11%) died in the year after transplantation, 11 of progressive disease and 1 of massive pulmonary embolism. These patients were not included in the analysis. Of the remaining 99 patients, 32 (32%) had documented infections in the year after transplantation. The most common outpatient infections documented were upper respiratory tract infections ( ), dern p 11 matomal zoster ( ), and urinary tract infections ( ); n p 9 n p 6 each occurred a mean of 5 months after transplantation.
All cases of zoster were limited to 1-2 dermatomes, and the majority occurred within 6 months of transplantation. Six of 9 patients who developed zoster had positive results of pretransplantation varicella-zoster virus serology studies, 2 had negative results, and 1 had unknown results. The only 2 patients who received systemic steroids during the year of outpatient follow-up both developed zoster during their steroid course. Seven of 9 patients who developed zoster were treated with oral acyclovir, and 2 were treated with outpatient iv acyclovir. Of the 9 patients with zoster, 1 developed postherpetic neuralgia and another developed a transient Bell's palsy. Central venous catheter-related infections were also relatively common in the outpatients ( ); all occurred shortly after discharge from n p 6 the hospitalization for inpatient transplantation.
Four hospitalizations for infections occurred in the year of follow-up. Two of these were for central venous catheter-associated infections. One patient was briefly hospitalized 8 months after transplantation for severe bronchitis, which resolved with iv antibiotics. Another patient was hospitalized 4 months after transplantation with Escherichia coli bacteremia (source unclear); she recovered with iv antibiotic therapy.
DISCUSSION
Although much is known about the rates of infection after allogeneic BMT, much less is known about infections occurring after autologous BMT or PSCT. Although several authors have investigated the rates of specific infections such as varicellazoster virus [11] and cytomegalovirus [12] in this setting, there are little data on the overall rates of infection immediately after and in the year after autologous BMT or PSCT. Moreover, interpretation of the existing data is complicated by the small patient populations in some studies and the inclusion of patients with both solid tumors and hematologic malignancies in other studies. To our knowledge, ours is the first study to address the overall incidence of both early and late infections in patients receiving high-dose chemotherapy followed by autologous BMT or PSCT in the treatment of a single solid tumor-namely, breast cancer.
In the context of universal growth factor support, the duration of neutropenia we observed (mean, 10 days) was brief, although almost all patients (98%) developed neutropenic fever. All patients except 1 in our study received broad-spectrum antibiotics. Infectious complications were more common in patients aged 150 years and in those who received high-dose chemotherapy followed by autologous BMT rather than PSCT ( ). The P ! .05 most common microbiologically documented infections identified in our study group were bacteremias (13%) and C. difficile colitis (10%). In patients with bacteremia, gram-positive isolates were as common as gram-negative isolates, consistent with na-tional trends observed since the use of indwelling catheters became common. Only 1 of the patients with bacteremia died.
C. difficile colitis was a common infection after transplantation. Patients with this infection did not differ from the remainder of the patients studied in regard to age, duration of neutropenia, length of hospital stay, or days of antibiotic therapy. It is of interest that of the 13 patients with C. difficile colitis, the hospital stays of 7 overlapped with the stay of at least 1 other patient on the oncology ward who developed C. difficile infection, which raises the possibility of nosocomial transmission. Whether differences in chemotherapy conditioning regimens may have played a role in the development of C. difficile colitis is not clear.
The frequency of nonbacterial infections in the immediate posttransplantation setting was low. In our study group, 72% of patients received fluconazole prophylaxis, and there was only 1 serious fungal infection, a case of candidemia (1%; 95% CI, 0-4). Our findings are similar to those noted in 2 similar studies [1, 13] . It is interesting to note that the dose of prophylactic fluconazole used was lower than the dose used in previous clinical trials (200 mg orally q.d.). In our group, only 31% of patients received AmB, and only 54% of patients with fever for у7 days received AmB. Clearly, optimal strategies for the prevention and empiric treatment of fungal infections in this setting should be reevaluated. It is possible that a strategy of widespread antifungal prophylaxis and early empiric therapy may not be warranted, but given the low number of patients in our study group who did not receive fluconazole prophylaxis, further study on this point is warranted.
Viral infections were also infrequent in the immediate posttransplantation setting. Acyclovir prophylaxis was used in 60 patients (47%), 48 of whom were herpes simplex virus (HSV) seropositive and 12 of whom were HSV seronegative. There were only 4 documented HSV infections. All were mild oral mucositis in patients who did not receive acyclovir. No cases of cytomegalovirus infection or other disseminated viral infection were documented. Cases of viral infection may have been missed because prospective cultures were not performed for patients; however, our study also does not overestimate the number of viral infections by including cases of oral mucositis that were clinically judged to be due to HSV infection.
Infectious complications in the first year after the transplantation were infrequent. Interestingly, herpes zoster infection, which has been reported to occur in up to 20% of patients in the year after BMT [11] , was seen in only 8% of our patients, and all were successfully treated as outpatients, without any evidence of dissemination. Although hospitalizations in the year after BMT were infrequent, half of them were due to catheterrelated infections, raising the question of whether indwelling catheters should be removed before discharge, when feasible.
Our study benefits from the fact that we examined every consecutive patient who underwent high-dose chemotherapy followed by BMT or PSCT for the treatment of breast cancer in an attempt to better define the inherent risks of infection in this population. Our study is, however, limited by the fact that the patient population was drawn from a single institution and by the fact that the sample size was relatively small. Our research was also retrospective and we did not have detailed knowledge about why certain treatment decisions were made regarding prophylactic and empiric antibiotic treatment of the study population. Additionally, our attempt to document accurately the incidence of infection in the first year after transplantation may have been limited by the fact that many patients came to our referral center for their chemotherapy but received their primary care elsewhere. Although the oncology center maintains detailed correspondence with primary-care physicians and although attempts were made to obtain records relating to infections in these patients, it is possible that some episodes were missed.
